Are Biosimilars the Road to Certain Success or High Risk Venture?

Discover key global trends in the ambiguous biosimilars market during Frost & Sullivan’s complimentary webinar

WHEN:                6 pm BST on Thursday, 17 October 2013 
LOCATION:         Online, with free registration
SPEAKER:          Frost & Sullivan Life Sciences Senior Industry Analyst Deborah Toscano 

The biosimilars market is on the verge of transitioning from a state of infancy to an entrenched facet of healthcare.  Numerous biosimilars, or follow-on biologics, have been successfully launched in many countries outside the US. Lower cost biosimilar versions of more complex biologic therapies, such as monoclonal antibodies, are now eagerly awaited and expected to significantly affect healthcare costs, particularly in the US, the largest market for biotechnology. However, residual uncertainties surrounding approval and commercial uptake could considerably influence the true potential of this market.   

Attend this webinar to:

·        Discover the issues around regulatory and payer acceptance of biosimilars in the US 
·        Learn how biosimilars are forecast to penetrate various biopharmaceutical segments and therapeutic areas 
·        Understand the potential risks and rewards of this market 
·        Gain insight into the competitive environment and potential US market leaders 
·        Identify the key factors with potential to impact the uptake of biosimilars. 

This briefing will benefit biopharmaceutical industry market participants, investors, pharmacy benefit managers, as well as physicians and other healthcare community members who desire an in-depth analysis of the biosimilars market.

Supporting Quote

“Biosimilars has been one of the hottest pharma and biotech topics for several years now, and one fraught with much uncertainty, particularly the US market,” says Life Sciences Senior Industry Analyst Deborah Toscano.  “Availability of follow-on versions of blockbuster monoclonal antibody therapies facing looming patent expiration, such as Humira and Erbitux, are anticipated to make a significant dent in healthcare spend. However, important differences between the biosimilars market and that of conventional generics make the accuracy of such predictions difficult, if not impossible.”

Supporting Resources

For more information about Frost & Sullivan’s Life Sciences practice, please visit: www.lifesciences.frost.com

Registration

•        To attend the briefing, email [email protected] your full name, job title, company name, company telephone number, company email address and website, city, state and country.

•        Receive a recorded version of the briefing anytime by submitting the aforementioned contact details.